VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Type of subject: outpatient                        │ Type of subject: outpatient                        │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Informed consent: Subjects must give their signed  │ Informed consent: Subjects must give their signed  │     100 │
│ and dated written informed consent to participate  │ and dated written informed consent to participate  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Gender: Male or female. Female subjects must be    │ Gender: Male or female. Female subjects must be    │     100 │
│ post-menopausal or using a highly effective method │ post-menopausal or using a highly effective method │         │
│ for avoidance of pregnancy. The decision to        │ for avoidance of pregnancy. The decision to        │         │
│ include or exclude women of childbearing potential │ include or exclude women of childbearing potential │         │
│ may be made at the discretion of the investigator  │ may be made at the discretion of the investigator  │         │
│ in accordance with local practice in relation to   │ in accordance with local practice in relation to   │         │
│ adequate contraception                             │ adequate contraception                             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Tobacco use: Subjects with a current or prior      │ Tobacco use: Subjects with a current or prior      │     100 │
│ history of \>=10 pack-years of cigarette smoking   │ history of >=10 pack-years of cigarette smoking at │         │
│ at screening (Visit 1). Previous smokers are       │ screening (Visit 1). Previous smokers are defined  │         │
│ defined as those who have stopped smoking for at   │ as those who have stopped smoking for at least 6   │         │
│ least 6 months prior to Visit 1                    │ months prior to Visit 1                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Airflow Obstruction                                │ Airflow Obstruction                                │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects with a measured post-albuterol/salbutamol │ Subjects with a measured post-albuterol/salbutamol │     100 │
│ forced expiratory volume in 1 second               │ forced expiratory volume in 1 second               │         │
│ (FEV1)/(forced vital capacity)FVC ratio of \<=0.70 │ (FEV1)/(forced vital capacity)FVC ratio of <=0.70  │         │
│ at Screening (Visit 1)                             │ at Screening (Visit 1)                             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Post-bronchodilator spirometry will be performed   │ Post-bronchodilator spirometry will be performed   │     100 │
│ approximately 15 minutes after the subject has     │ approximately 15 minutes after the subject has     │         │
│ self-administered 4 inhalations (i.e., total       │ self-administered 4 inhalations (i.e., total       │         │
│ 400mcg) of albuterol/salbutamol via a metered dose │ 400mcg) of albuterol/salbutamol via a metered dose │         │
│ inhaler (MDI )with a valved-holding chamber. The   │ inhaler (MDI )with a valved-holding chamber. The   │         │
│ FEV1/FVC ratio and FEV1 percent predicted values   │ FEV1/FVC ratio and FEV1 percent predicted values   │         │
│ will be calculated                                 │ will be calculated                                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Symptoms of COPD: Subjects must score 2 or higher  │ Symptoms of COPD: Subjects must score 2 or higher  │     100 │
│ on the modified Medical Research Council Dyspnea   │ on the modified Medical Research Council Dyspnea   │         │
│ scale (Visit 1)                                    │ scale (Visit 1)                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Cardiovascular disease                             │ Cardiovascular disease                             │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Established (i.e. by clinical signs or imaging     │ Established (i.e. by clinical signs or imaging     │     100 │
│ studies) coronary artery disease (CAD) Established │ studies) coronary artery disease (CAD) Established │         │
│ (i.e. by clinical signs or imaging studies)        │ (i.e. by clinical signs or imaging studies)        │         │
│ peripheral vascular disease (PVD) Previous stroke  │ peripheral vascular disease (PVD) Previous stroke  │         │
│ Previous MI Diabetes mellitus with target organ    │ Previous MI Diabetes mellitus with target organ    │         │
│ disease OR                                         │ disease OR                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Being treated for hypercholesterolemia Being       │ Being treated for hypercholesterolemia Being       │     100 │
│ treated for hypertension Being treated for         │ treated for hypertension Being treated for         │         │
│ diabetes mellitus Being treated for peripheral     │ diabetes mellitus Being treated for peripheral     │         │
│ vascular disease                                   │ vascular disease                                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Pregnancy: Women who are pregnant or lactating     │ Pregnancy: Women who are pregnant or lactating     │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Asthma: Subjects with a current diagnosis of       │ Asthma: Subjects with a current diagnosis of       │     100 │
│ asthma. (Subjects with a prior history of asthma   │ asthma. (Subjects with a prior history of asthma   │         │
│ are eligible if they also have a current diagnosis │ are eligible if they also have a current diagnosis │         │
│ of COPD)                                           │ of COPD)                                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ alpha 1-antitrypsin deficiency: Subjects with      │ alpha 1-antitrypsin deficiency: Subjects with      │     100 │
│ known alpha-1 antitrypsin deficiency as the        │ known alpha-1 antitrypsin deficiency as the        │         │
│ underlying cause of COPD                           │ underlying cause of COPD                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Other respiratory disorders: Subjects with active  │ Other respiratory disorders: Subjects with active  │     100 │
│ tuberculosis, lung cancer, bronchiectasis,         │ tuberculosis, lung cancer, bronchiectasis,         │         │
│ sarcoidosis, pulmonary fibrosis, pulmonary         │ sarcoidosis, pulmonary fibrosis, pulmonary         │         │
│ hypertension, interstitial lung diseases or other  │ hypertension, interstitial lung diseases or other  │         │
│ active pulmonary diseases                          │ active pulmonary diseases                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Lung resection or transplantation: Subjects with   │ Lung resection or transplantation: Subjects with   │     100 │
│ lung volume reduction surgery within the 12 months │ lung volume reduction surgery within the 12 months │         │
│ prior to Screening or having had a lung transplant │ prior to Screening or having had a lung transplant │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ A moderate/severe COPD exacerbation that has not   │ A moderate/severe COPD exacerbation that has not   │     100 │
│ resolved at least 14 days prior to Visit 1 and at  │ resolved at least 14 days prior to Visit 1 and at  │         │
│ least 30 days following the last dose of oral      │ least 30 days following the last dose of oral      │         │
│ corticosteroids (if applicable)                    │ corticosteroids (if applicable)                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Current severe heart failure (New York Heart       │ Current severe heart failure (New York Heart       │     100 │
│ Association class IV). Subjects will also be       │ Association class IV). Subjects will also be       │         │
│ excluded if they have a known ejection fraction of │ excluded if they have a known ejection fraction of │         │
│ \<30% or if they have an implantable cardioverter  │ <30% or if they have an implantable cardioverter   │         │
│ defibrillator (ICD)                                │ defibrillator (ICD)                                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Other diseases/abnormalities: Any life-threatening │ Other diseases/abnormalities: Any life-threatening │     100 │
│ condition with life expectancy \<3 years, other    │ condition with life expectancy <3 years, other     │         │
│ than vascular disease or COPD, that might prevent  │ than vascular disease or COPD, that might prevent  │         │
│ the subject from completing the study              │ the subject from completing the study              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ End stage chronic renal disease: Subjects will be  │ End stage chronic renal disease: Subjects will be  │     100 │
│ excluded if on renal replacement therapy           │ excluded if on renal replacement therapy           │         │
│ (hemodialysis or peritoneal)                       │ (hemodialysis or peritoneal)                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Drug/food allergy: Subjects with a history of      │ Drug/food allergy: Subjects with a history of      │     100 │
│ hypersensitivity to any of the study medications   │ hypersensitivity to any of the study medications   │         │
│ (e.g. beta-agonists, corticosteroid) or components │ (e.g. beta-agonists, corticosteroid) or components │         │
│ of the inhalation powder (e.g. lactose, magnesium  │ of the inhalation powder (e.g. lactose, magnesium  │         │
│ stearate). In addition, patients with a history of │ stearate). In addition, patients with a history of │         │
│ severe milk protein allergy that, in the opinion   │ severe milk protein allergy that, in the opinion   │         │
│ of the study physician, contraindicates the        │ of the study physician, contraindicates the        │         │
│ subject's participation will also be excluded      │ subject's participation will also be excluded      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Drug/alcohol abuse: Subjects with a known or       │ Drug/alcohol abuse: Subjects with a known or       │     100 │
│ suspected history of alcohol or drug abuse within  │ suspected history of alcohol or drug abuse within  │         │
│ the last 2 years                                   │ the last 2 years                                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Oxygen therapy: Subjects receiving treatment with  │ Oxygen therapy: Subjects receiving treatment with  │     100 │
│ long-term oxygen therapy (LTOT) or nocturnal       │ long-term oxygen therapy (LTOT) or nocturnal       │         │
│ oxygen therapy required for greater than 12 hours  │ oxygen therapy required for greater than 12 hours  │         │
│ a day. Oxygen prn use (i.e. \<=12 hours per day)   │ a day. Oxygen prn use (i.e. <=12 hours per day) is │         │
│ is not exclusionary                                │ not exclusionary                                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Questionable validity of consent: Subjects with a  │ Questionable validity of consent: Subjects with a  │     100 │
│ history of psychiatric disease, intellectual       │ history of psychiatric disease, intellectual       │         │
│ deficiency, poor motivation or other conditions    │ deficiency, poor motivation or other conditions    │         │
│ that will limit the validity of informed consent   │ that will limit the validity of informed consent   │         │
│ to participate in the study or the potential       │ to participate in the study or the potential       │         │
│ compliance to study procedures                     │ compliance to study procedures                     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Affiliation with investigator site: Study          │ Affiliation with investigator site: Study          │     100 │
│ investigators, sub-investigators, study            │ investigators, sub-investigators, study            │         │
│ coordinators, employees of a participating         │ coordinators, employees of a participating         │         │
│ investigator or immediate family members of the    │ investigator or immediate family members of the    │         │
│ aforementioned are excluded from participating in  │ aforementioned are excluded from participating in  │         │
│ this study                                         │ this study                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Additional medication: Use of the following        │ Additional medication: Use of the following        │     100 │
│ medications within the following time intervals    │ medications within the following time intervals    │         │
│ prior to Visit 1 or during the study (unless       │ prior to Visit 1 or during the study (unless       │         │
│ otherwise specified)                               │ otherwise specified)                               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Medication No use within the following time        │ Medication No use within the following time        │     100 │
│ intervals prior to Screening or thereafter at any  │ intervals prior to Screening or thereafter at any  │         │
│ time during the study (unless otherwise specified) │ time during the study (unless otherwise specified) │         │
│ Inhaled Long acting beta-agonists (LABA) 48 hours  │ Inhaled Long acting beta-agonists (LABA) 48 hours  │         │
│ ICS/LABA combination products 48 hours Inhaled     │ ICS/LABA combination products 48 hours Inhaled     │         │
│ corticosteroids 48 hours Tiotropium 1 week         │ corticosteroids 48 hours Tiotropium 1 week         │         │
│ Systemic, Oral, parenteral, intra-articular        │ Systemic, Oral, parenteral, intra-articular        │         │
│ corticosteroids 30 days (oral and systemic         │ corticosteroids 30 days (oral and systemic         │         │
│ corticosteroids may be used to treat COPD          │ corticosteroids may be used to treat COPD          │         │
│ exacerbations during the study) Cytochrome P450    │ exacerbations during the study) Cytochrome P450    │         │
│ 3A4 strong inhibitors including but not limited to │ 3A4 strong inhibitors including but not limited to │         │
│ antiretrovirals (protease inhibitors)              │ antiretrovirals (protease inhibitors)              │         │
│ (e.g.Indinavir, Nelfinavir, Ritonavir,             │ (e.g.Indinavir, Nelfinavir, Ritonavir,             │         │
│ Saquinavir); Imidazole and Triazole anti-fungals   │ Saquinavir); Imidazole and Triazole anti-fungals   │         │
│ (e.g. Ketaconazole, Itraconazole); Clarithromycin, │ (e.g. Ketaconazole, Itraconazole); Clarithromycin, │         │
│ Telithromycin, Amiodarone, and Nefazodone 6 weeks  │ Telithromycin, Amiodarone, and Nefazodone 6 weeks  │         │
│ Grapefruit is allowed up to Visit 1, then limited  │ Grapefruit is allowed up to Visit 1, then limited  │         │
│ to no more than one glass of grapefruit juice (250 │ to no more than one glass of grapefruit juice (250 │         │
│ mL/ 8 ounces) or one grapefruit per day Any other  │ mL/ 8 ounces) or one grapefruit per day Any other  │         │
│ investigational drug 30 days or 5 half lives       │ investigational drug 30 days or 5 half lives       │         │
│ whichever is longer                                │ whichever is longer                                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Age: \>=40 and \<=80 years of age at Screening     │ Age: >=40 and <=80 years of age at Screening       │      98 │
│ (Visit 1)                                          │ (Visit 1)                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects with a measured post-albuterol/salbutamol │ Subjects with a measured post-albuterol/salbutamol │      99 │
│ FEV1 \>=50 and \<=70% of predicted normal values   │ FEV1 >=50 and <=70% of predicted normal values     │         │
│ calculated using NHANES III reference equations    │ calculated using NHANES III reference equations    │         │
│ \[Hankinson, 1999; Hankinson, 2010\] at Screening  │ [Hankinson, 1999; Hankinson, 2010] at Screening    │         │
│ (Visit 1)                                          │ (Visit 1)                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ For patients \>= 40 years of age: any one of the   │ For patients >= 40 years of age: any one of the    │      99 │
│ following                                          │ following                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ For patients \>=60 years of age: any 2 of the      │ For patients >=60 years of age: any 2 of the       │      99 │
│ following                                          │ following                                          │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤══════════════════════════════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria                                │   Score │
╞═══════════════════════════════════╪══════════════════════════════════════════════╪═════════╡
│ Must have minimum age of 40 Years │ Age: >=40 and <=80 years of age at Screening │      30 │
│                                   │ (Visit 1)                                    │         │
├───────────────────────────────────┼──────────────────────────────────────────────┼─────────┤
│ Must have maximum age of 80 Years │ Cardiovascular disease                       │      33 │
╘═══════════════════════════════════╧══════════════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 99
Average Levenshtein Ratio of individual lines: 95.6969696969697
OverAll Ratio: 97.34848484848484
